We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
- Authors
Hwang, Catherine J; Nichols, Erin E; Chon, Brian H; Perry, Julian D
- Abstract
Thyroid eye disease is an auto-immune mediated orbitopathy which can cause dysthyroid compressive optic neuropathy. Traditional management of active thyroid eye disease includes temporizing high-dose steroids, orbital radiation and surgical decompression, which each possess significant limitations and/or side effects. Teprotumumab is an IGF-IR inhibitor recently FDA-approved for active thyroid eye disease. The authors report reversal of bilateral dysthyroid compressive optic neuropathy managed medically utilizing teprotumumab.
- Publication
European Journal of Ophthalmology, 2022, Vol 32, Issue 3, pNP46
- ISSN
1120-6721
- Publication type
Article
- DOI
10.1177/1120672121991042